Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Oct 12, 2022
- Accession no.
- 0001447362-22-000162
- Filed
- Oct 12, 2022
- Trade date
- Oct 11, 2022
- Filing delay
- 1 day
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 5 non-derivative transactions. Open-market sales total $13.5K. It was filed 1 day after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Oct 11, 2022 | Common Stock | SSaleDisposed | −301 | $24.05F2 | −$7,239.05 | 122,724 | Indirect | |
| Oct 11, 2022 | Common Stock | SSaleDisposed | −65 | $24.05F2 | −$1,563.25 | 27,349 | Indirect | |
| Oct 11, 2022 | Common Stock | SSaleDisposed | −64 | $24.05F2 | −$1,539.2 | 27,347 | Indirect | |
| Oct 11, 2022 | Common Stock | SSaleDisposed | −64 | $24.05F2 | −$1,539.2 | 27,347 | Indirect | |
| Oct 11, 2022 | Common Stock | SSaleDisposed | −66 | $24.05F2 | −$1,587.3 | 27,342 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $23.63 to $24.30, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 5 transactions in Table I.
Remarks
This Form 4 is the second of two Form 4s being filed by the Reporting Person relating to the same event. The Form 4 has been split into two filings to cover all 35 individual transactions that occurred on the same Transaction Date, because the SEC's EDGAR filing system limits a single Form 4 to a maximum of 30 separate transactions.